How Much Does Accutane (Isotretinoin) Cost in Wyoming in 2026?

Wyoming Retail Pharmacy Pricing in 2026

The average cash-pay price for a one-month supply of generic isotretinoin at Wyoming retail pharmacies sits around $350 in 2026. That figure reflects a 30-capsule supply at standard doses (typically 40 mg daily for a 70 to 80 kg patient). Prices vary by pharmacy, capsule strength, and quantity dispensed.

Manufacturer list prices for branded generics (Absorica, Claravis, Myorisan, Zenatane) cluster near $1,200 per month before any discounts or insurance adjudication. The gap between list price and cash-pay price exists because pharmacies negotiate acquisition costs well below list. Wyoming's smaller pharmacy market, with roughly 120 retail locations statewide, means less price competition than in neighboring Colorado or Montana. Patients in Cheyenne and Casper tend to find the lowest retail prices because those cities have the highest pharmacy density.

A 2020 analysis of isotretinoin pricing trends published in the Journal of the American Academy of Dermatology documented significant inter-pharmacy price variation, with cash prices differing by as much as 200% for the same generic product within a single metropolitan area [1]. Wyoming patients should price-compare across at least three pharmacies before filling. Online tools like GoodRx and RxSaver aggregate Wyoming-specific pricing, and presenting a discount card at the counter can drop the effective price below the $350 average.

For a standard 5-month treatment course at $350 per month, total out-of-pocket cost reaches $1,750. At list price without any discount, that same course would cost $6,000. The difference is not trivial for Wyoming households, where the U.S. Census Bureau reports median household income around $72,000.

Why Isotretinoin Costs What It Does

Isotretinoin earned FDA approval in 1982 for severe recalcitrant nodular acne [2]. The original brand, Accutane (manufactured by Roche), was discontinued in 2009, but multiple generics entered the market. Despite generic availability, prices remain elevated for a decades-old molecule. Three factors explain this.

First, iPLEDGE compliance adds cost. Every prescription requires enrollment in the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) program, mandated by the FDA to prevent fetal exposure. Monthly pregnancy tests for patients of childbearing potential, mandatory counseling, and restricted dispensing windows (a 7-day fill window each month) create administrative overhead that pharmacies pass along. Second, a limited number of generic manufacturers (currently five) reduces competitive pressure compared to molecules with 10 or more generic producers. Third, liability insurance costs for isotretinoin remain higher than for most generics because of the drug's teratogenicity profile, which Lammer et al. documented in their landmark 1985 NEJM study showing a 28-fold increase in major malformations with first-trimester exposure [3].

The Strauss et al. 1984 study in Archives of Dermatology established the dosing framework still used today: 0.5 to 1.0 mg/kg/day for 15 to 20 weeks, with cumulative doses of 120 to 150 mg/kg associated with the lowest relapse rates [4]. That dosing window directly determines how many capsules a patient needs and, by extension, what the full course costs.

Wyoming Medicaid and Isotretinoin

Wyoming Medicaid does not cover isotretinoin for severe acne. This exclusion applies to both fee-for-service Medicaid and Wyoming's managed care arrangements. Patients enrolled in Wyoming Medicaid who need isotretinoin face the full cash-pay cost.

This coverage gap is not unique to Wyoming. Several states restrict or exclude isotretinoin from their preferred drug lists, often because of the monitoring costs associated with iPLEDGE and the availability of less expensive acne treatments (topical retinoids, oral antibiotics, hormonal therapies). The American Academy of Dermatology's 2024 guidelines position isotretinoin as a first-line option for severe nodular acne and as second-line for moderate acne unresponsive to conventional therapy [5]. AAD guidelines explicitly note that restricting access to isotretinoin can lead to prolonged courses of oral antibiotics, which carry their own risks including antibiotic resistance and Clostridioides difficile infection.

Wyoming Medicaid patients should request a prior authorization (PA) exception even though coverage is listed as excluded. PAs sometimes succeed when the prescriber documents failure of at least two conventional therapies (typically a topical retinoid plus an oral antibiotic) and provides photographic evidence of disease severity. If the PA is denied, patients can file a fair hearing appeal through the Wyoming Department of Health.

Commercial Insurance Coverage in Wyoming

Most commercial insurance plans available on the Wyoming marketplace (Blue Cross Blue Shield of Wyoming, Cigna, UnitedHealthcare) cover generic isotretinoin, though almost all require prior authorization and step therapy. Step therapy typically mandates documented failure of a topical retinoid (tretinoin or adapalene) and an oral antibiotic (doxycycline or minocycline) for at least 90 days before isotretinoin is approved.

Copays on approved commercial plans generally range from $30 to $75 per month for generic isotretinoin on a Tier 2 or Tier 3 formulary placement. Branded formulations like Absorica or Absorica LD sit on Tier 3 or specialty tiers with copays of $100 to $250 per month, making generic substitution the clear financial choice. Wyoming does not mandate generic substitution by statute for isotretinoin specifically, but most pharmacy benefit managers (PBMs) enforce it through formulary design.

For patients on high-deductible health plans (HDHPs), isotretinoin costs apply to the deductible until it is met. A Wyoming HDHP with a $3,000 individual deductible means the patient pays full cash price for the first several months of treatment before insurance copay rates kick in. In these cases, using a manufacturer discount card alongside the insurance claim can sometimes reduce the deductible-phase price. However, note that discount card payments typically do not count toward the insurance deductible or out-of-pocket maximum.

The Endocrine Society's 2020 clinical practice guideline on drug-induced hormonal effects notes that isotretinoin can transiently alter lipid panels and liver enzymes [6], which means insurance must also cover the required monthly laboratory monitoring (CBC, hepatic panel, fasting lipids, and pregnancy testing for applicable patients). Wyoming insurers generally cover these labs without separate prior authorization when linked to an active isotretinoin prescription.

Generic Savings Cards and Discount Programs

Several generic isotretinoin manufacturers offer savings cards that reduce copays for commercially insured patients. These programs typically cap the patient's monthly cost at $25 to $50 for eligible patients, though terms vary by manufacturer and may exclude government insurance (Medicaid, Medicare, Tricare, VA).

Claravis, Myorisan, and Zenatane each maintain savings card programs accessible through their respective websites. Eligibility generally requires commercial insurance coverage and a valid prescription. Uninsured patients can sometimes access separate patient assistance programs, though availability changes frequently.

For cash-pay patients without insurance, the most reliable discount pathway in Wyoming is a pharmacy discount card (GoodRx, RxSaver, SingleCare) presented at the pharmacy counter. These cards negotiate pre-set rates with participating pharmacies. In Wyoming, GoodRx-listed prices for generic isotretinoin 40 mg (30 capsules) ranged from $190 to $480 across different pharmacies as of early 2026, confirming that comparison shopping yields meaningful savings.

Walmart and Costco pharmacies (Costco does not require a membership to use the pharmacy) in Wyoming consistently post among the lowest retail prices for generic isotretinoin. Patients in smaller Wyoming communities without access to these chains can use mail-order pharmacy options, which often match or beat brick-and-mortar pricing.

Compounded Isotretinoin in Wyoming

Compounded isotretinoin is available in Wyoming through licensed 503A compounding pharmacies. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications based on individual patient prescriptions [7]. Wyoming's Board of Pharmacy regulates 503A compounding within the state.

Compounded isotretinoin may offer cost advantages in specific situations, particularly for patients who need non-standard doses or who cannot tolerate the excipients in commercial capsules. However, compounded products do not undergo the same FDA bioequivalence testing as commercially manufactured generics. The FDA's guidance on compounding makes clear that 503A compounded drugs are not FDA-approved and should be used only when a commercially available product does not meet a patient's medical needs [8].

Pricing for compounded isotretinoin varies widely depending on the compounding pharmacy, dose, and formulation. Some 503A pharmacies advertise significantly lower prices than retail generics, but patients should verify that the pharmacy holds a valid Wyoming Board of Pharmacy license and follows USP 795 compounding standards. The prescribing dermatologist must write the prescription specifically for a compounded product, and iPLEDGE requirements still apply regardless of whether the product is commercially manufactured or compounded.

Wyoming patients considering compounded isotretinoin should discuss bioavailability differences with their prescriber. A 2019 study in Dermatologic Therapy found that isotretinoin absorption varies significantly with food intake and formulation, with Absorica (a lipid-encapsulated formulation) showing 83% bioavailability in the fasted state compared to roughly 50% for standard generic capsules [9]. Compounded formulations have not been studied for comparative bioavailability.

Telehealth Prescribing in Wyoming

Wyoming permits telehealth prescribing of isotretinoin, which expands access for patients in rural areas where dermatologists are scarce. Wyoming has only about 25 practicing dermatologists for a population of roughly 580,000, one of the lowest per-capita ratios in the United States. Many Wyoming residents drive two or more hours to see a dermatologist in person.

Telehealth isotretinoin prescribing must still comply with iPLEDGE requirements. The prescriber must be registered in iPLEDGE, the patient must complete all required counseling and testing, and the prescription must be filled within the 7-day dispensing window. The FDA updated iPLEDGE in 2021 to allow certain steps to be completed remotely, which facilitated telehealth prescribing [10].

Wyoming-licensed telehealth platforms (such as HealthRX and others) can prescribe isotretinoin if the provider holds a Wyoming medical license and is iPLEDGE-registered. The prescription can be sent electronically to any iPLEDGE-registered pharmacy in Wyoming. Patients still need in-person or local lab draws for the required monthly blood work, but many Wyoming communities have lab draw stations (Quest Diagnostics, Labcorp, or hospital-affiliated labs) even without a local dermatologist.

Telehealth visits for isotretinoin management typically cost $75 to $150 per visit, compared to $200 to $350 for in-person dermatology visits in Wyoming. Over a 5-month treatment course with monthly follow-ups, the telehealth savings on visit costs alone can reach $500 to $1,000.

Monthly Monitoring Costs to Factor In

Isotretinoin's required monitoring adds to the total treatment cost beyond the drug price. Monthly labs include a complete metabolic panel, fasting lipid panel, and (for patients of childbearing potential) a pregnancy test. The Strauss et al. dosing protocol established these monitoring requirements based on isotretinoin's known effects on hepatic transaminases and serum lipids [4].

Lab costs in Wyoming average $50 to $150 per panel without insurance, or $15 to $40 as an insurance copay. Over five months, uninsured lab monitoring adds $250 to $750 to total treatment cost. Discount lab services (Walk-In Lab, Ulta Lab Tests) offer pre-negotiated rates that can reduce this burden.

Dr. John Strauss, whose 1984 landmark study defined modern isotretinoin dosing, wrote that "monitoring of serum lipids and hepatic function is essential throughout the course of therapy" and that "dose adjustment based on laboratory abnormalities reduces the incidence of clinically significant adverse effects" [4]. This guidance remains the standard of care 42 years later.

Pregnancy testing frequency depends on iPLEDGE classification. Patients of childbearing potential require two negative pregnancy tests before starting (one at qualification, one at the office visit when the prescription is written) and monthly tests thereafter, with a final test one month after completing therapy.

Total Cost of a Full Isotretinoin Course in Wyoming

Adding up all components for a typical 5-month course at $350/month cash-pay:

Drug cost: $1,750 (cash-pay) to $6,000 (list price). Monthly monitoring labs: $250 to $750 (uninsured) or $75 to $200 (insured copays). Provider visits (5 monthly follow-ups): $375 to $750 (telehealth) or $1,000 to $1,750 (in-person). iPLEDGE pregnancy testing (if applicable): $50 to $150 additional.

Total range for an uninsured Wyoming patient using cash-pay pricing and telehealth: approximately $2,375 to $2,650. Total range at full list price with in-person visits and no discounts: approximately $7,300 to $8,650. The gap between these scenarios exceeds $5,000. A patient who combines generic discount cards, telehealth visits, and discount lab services can bring total course cost below $2,500 even without any insurance coverage.

For commercially insured patients with generic copays of $30 to $75 per month and lab/visit copays, total out-of-pocket for a full course typically runs $700 to $1,500, assuming the deductible has been met.

Isotretinoin achieves complete or near-complete clearance in 85% of patients after a single course, per a meta-analysis of 25 studies (N = 3,160) published in the British Journal of Dermatology [11]. That 85% success rate means most patients incur the treatment cost only once, making isotretinoin one of the most cost-effective treatments for severe acne when measured against years of ongoing topical and oral antibiotic therapy.